{"id":1508,"date":"2021-10-25T12:24:12","date_gmt":"2021-10-25T12:24:12","guid":{"rendered":"http:\/\/3.8.237.186\/?post_type=team&#038;p=1508"},"modified":"2022-09-14T17:40:47","modified_gmt":"2022-09-14T17:40:47","slug":"robert-bob-sikorski-md-phd","status":"publish","type":"team","link":"https:\/\/avellino.ai\/sg\/team\/robert-bob-sikorski-md-phd\/","title":{"rendered":"Robert (Bob) Sikorski, MD, PhD"},"content":{"rendered":"<p>Managing Director, Woodside Way Ventures, Former Organizations: Five Prime Therapeutics, Medimmune, Amgen, Genzyme, Mednav, Inc.<\/p>\n<p>Dr Sikorski is an independent drug developer focusing on advancing next-generation therapeutics through his company Woodside Way Ventures. Previously, as the Chief Medical Officer of FivePrime Therapeutics, he built a development organization, led clinical programs that advanced oncology drugs, and led the steering committee that managed a $350 million partnership agreement with BMS. As a Senior Director of Global Oncology Research and Development at Medimmune, he managed a clinical portfolio of 6 protein-based therapeutics in Phase l and ll clinical trials. They developed the initial PDL1 x CTLA4 combination regimen that advanced to a Phase III in lung cancer. As a Director of Global Oncology Research and Development at Amgen, he was instrumental in advancing a successful pivotal Phase III trial for Vectibix that gained European Marketing Authorization based on the first gene mutation companion diagnostic in colorectal cancer. Bob was also a medical affairs advisor to Genzyme and a CTO at Mednav, Inc. He is board-certified in both oncology and internal medicine. He has served as an editor for Science magazine and the Journal of the American Medical Association.<\/p>","protected":false},"excerpt":{"rendered":"<p>Managing Director, Woodside Way Ventures, Former Organizations: Five Prime Therapeutics, Medimmune, Amgen, Genzyme, Mednav, Inc. Dr Sikorski is an independent drug developer focusing on advancing next-generation therapeutics through his company Woodside Way Ventures. Previously, as the Chief Medical Officer of FivePrime Therapeutics, he built a development organization, led clinical programs that advanced oncology drugs, and [&hellip;]<\/p>\n","protected":false},"featured_media":1568,"template":"","meta":{"_eb_attr":"","_links_to":"","_links_to_target":""},"categories":[45],"tags":[],"class_list":["post-1508","team","type-team","status-publish","has-post-thumbnail","hentry","category-executive-advisory-committee"],"acf":[],"_links":{"self":[{"href":"https:\/\/avellino.ai\/sg\/wp-json\/wp\/v2\/team\/1508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/avellino.ai\/sg\/wp-json\/wp\/v2\/team"}],"about":[{"href":"https:\/\/avellino.ai\/sg\/wp-json\/wp\/v2\/types\/team"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/avellino.ai\/sg\/wp-json\/wp\/v2\/media\/1568"}],"wp:attachment":[{"href":"https:\/\/avellino.ai\/sg\/wp-json\/wp\/v2\/media?parent=1508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/avellino.ai\/sg\/wp-json\/wp\/v2\/categories?post=1508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/avellino.ai\/sg\/wp-json\/wp\/v2\/tags?post=1508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}